亚洲房颤患者的直接口服抗凝剂：亚太心脏病学会关于血栓和出血风险管理策略的共识建议

2021-07-01 亚太心脏病协会APSC Eur Cardiol . 2021 May 28;16:e23. doi: 10.15420/ecr.2020.43

亚太地区 AF 的疾病负担比世界其他地区更大。直接口服抗凝剂 (DOAC) 已成为维生素 K 拮抗剂 (VKA) 的有效替代品，可用于预防 AF 患者的血栓栓塞事件。亚太心脏病学会制定了这一共识声

中文标题：

发布机构：

亚太心脏病协会APSC

发布日期：

2021-07-01

简要介绍：

亚太地区 AF 的疾病负担比世界其他地区更大。直接口服抗凝剂 (DOAC) 已成为维生素 K 拮抗剂 (VKA) 的有效替代品，可用于预防 AF 患者的血栓栓塞事件。亚太心脏病学会制定了这一共识声明，以指导医生管理亚洲人群的 AF。声明由专家共识小组制定，该小组审查了亚太地区患者的可用数据。制定了共识声明，然后进行在线投票。由此产生的 17 项声明为评估该地区 AF 患者的卒中风险、在这些患者中适当使用 DOAC 以及同时使用 DOAC 和抗血小板药物以及从 VKA 向 DOAC 过渡以及反之亦然提供了指导。还讨论了 DOAC 治疗患者的围手术期管理和 DOAC 治疗期间出血患者的管理。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=da0541c002132302, title=亚洲房颤患者的直接口服抗凝剂：亚太心脏病学会关于血栓和出血风险管理策略的共识建议 , enTitle=, guiderFrom=Eur Cardiol . 2021 May 28;16:e23. doi: 10.15420/ecr.2020.43, authorId=0, author=, summary=亚太地区 AF 的疾病负担比世界其他地区更大。直接口服抗凝剂 (DOAC) 已成为维生素 K 拮抗剂 (VKA) 的有效替代品，可用于预防 AF 患者的血栓栓塞事件。亚太心脏病学会制定了这一共识声, cover=https://img.medsci.cn/20211214/1639463852251_1614372.png, journalId=0, articlesId=null, associationId=1944, associationName=亚太心脏病协会APSC, associationIntro=Asian Pacific Society of Cardiology (APSC), copyright=0, guiderPublishedTime=Thu Jul 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=亚太地区 AF 的疾病负担比世界其他地区更大。 直接口服抗凝剂 (DOAC) 已成为维生素 K 拮抗剂 (VKA) 的有效替代品，可用于预防 AF 患者的血栓栓塞事件。 亚太心脏病学会制定了这一共识声明，以指导医生管理亚洲人群的 AF。 声明由专家共识小组制定，该小组审查了亚太地区患者的可用数据。 制定了共识声明，然后进行在线投票。 由此产生的 17 项声明为评估该地区 AF 患者的卒中风险、在这些患者中适当使用 DOAC 以及同时使用 DOAC 和抗血小板药物以及从 VKA 向 DOAC 过渡以及反之亦然提供了指导。 还讨论了 DOAC 治疗患者的围手术期管理和 DOAC 治疗期间出血患者的管理。, tagList=[TagDto(tagId=364, tagName=房颤), TagDto(tagId=367, tagName=心房颤动)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=15012, appHits=199, showAppHits=0, pcHits=1121, showPcHits=14812, likes=2, shares=14, comments=14, approvalStatus=1, publishedTime=Fri Jul 16 20:57:19 CST 2021, publishedTimeString=2021-07-01, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Fri Jul 16 20:57:13 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Fri Jan 05 16:51:28 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])

66.pdf

下载请点击：

评论区 (12)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1180228, encodeId=c70f118022869, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=379a6445098, createdName=ms4000000479270390, createdTime=Mon Jan 03 23:37:35 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057156, encodeId=f393105e156de, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:30:39 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058020, encodeId=fbf51058020bc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03155479866, createdName=ms6000000932762500, createdTime=Wed Oct 06 07:39:35 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009999, encodeId=25c1100999998, content=来看看有啥新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ddb2622122, createdName=aimgoal2009, createdTime=Sat Aug 21 12:23:58 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007347, encodeId=53e6100e34715, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:57:53 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
2022-01-03 ms4000000479270390

很好

107 0
[GetPortalCommentsPageByObjectIdResponse(id=1180228, encodeId=c70f118022869, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=379a6445098, createdName=ms4000000479270390, createdTime=Mon Jan 03 23:37:35 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057156, encodeId=f393105e156de, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:30:39 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058020, encodeId=fbf51058020bc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03155479866, createdName=ms6000000932762500, createdTime=Wed Oct 06 07:39:35 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009999, encodeId=25c1100999998, content=来看看有啥新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ddb2622122, createdName=aimgoal2009, createdTime=Sat Aug 21 12:23:58 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007347, encodeId=53e6100e34715, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:57:53 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
2021-10-03 H8888888

学习了

113 0
[GetPortalCommentsPageByObjectIdResponse(id=1180228, encodeId=c70f118022869, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=379a6445098, createdName=ms4000000479270390, createdTime=Mon Jan 03 23:37:35 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057156, encodeId=f393105e156de, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:30:39 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058020, encodeId=fbf51058020bc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03155479866, createdName=ms6000000932762500, createdTime=Wed Oct 06 07:39:35 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009999, encodeId=25c1100999998, content=来看看有啥新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ddb2622122, createdName=aimgoal2009, createdTime=Sat Aug 21 12:23:58 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007347, encodeId=53e6100e34715, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:57:53 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
2021-10-06 ms6000000932762500

很好

121 0
[GetPortalCommentsPageByObjectIdResponse(id=1180228, encodeId=c70f118022869, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=379a6445098, createdName=ms4000000479270390, createdTime=Mon Jan 03 23:37:35 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057156, encodeId=f393105e156de, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:30:39 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058020, encodeId=fbf51058020bc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03155479866, createdName=ms6000000932762500, createdTime=Wed Oct 06 07:39:35 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009999, encodeId=25c1100999998, content=来看看有啥新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ddb2622122, createdName=aimgoal2009, createdTime=Sat Aug 21 12:23:58 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007347, encodeId=53e6100e34715, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:57:53 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
2021-08-21 aimgoal2009

来看看有啥新进展

122 0
[GetPortalCommentsPageByObjectIdResponse(id=1180228, encodeId=c70f118022869, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=379a6445098, createdName=ms4000000479270390, createdTime=Mon Jan 03 23:37:35 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057156, encodeId=f393105e156de, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:30:39 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058020, encodeId=fbf51058020bc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03155479866, createdName=ms6000000932762500, createdTime=Wed Oct 06 07:39:35 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009999, encodeId=25c1100999998, content=来看看有啥新进展, beContent=null, objectType=guider, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ddb2622122, createdName=aimgoal2009, createdTime=Sat Aug 21 12:23:58 CST 2021, time=2021-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007347, encodeId=53e6100e34715, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16dd5569788, createdName=ms9000000533661856, createdTime=Thu Aug 12 17:57:53 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
2021-08-12 ms9000000533661856

谢谢

136 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

亚洲房颤患者的直接口服抗凝剂：亚太心脏病学会关于血栓和出血风险管理策略的共识建议

相关指南

科室

工具

服务